Kovaltry

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Kovaltry
Generic name
ANTIHEMOPHILIC FACTOR (RECOMBINANT)
Manufacturer
Bayer HealthCare LLC
Product type
PLASMA DERIVATIVE
SPL set ID
89ba5048-469c-4f08-a173-81b0c6f3004d
SPL ID
f4bed724-db3e-448e-8947-2f6a6913f1ee
Version
18
Effective date
2026-03-02
Source export date
2026-11-13
Source partition
6
Source file
https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:20:42

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS • Hypersensitivity reactions, including anaphylaxis, are possible. Should symptoms occur, discontinue treatment with KOVALTRY and administer appropriate treatment ( 5.1 ). • Development of Factor VIII neutralizing antibodies has occurred. Perform an assay that measures Factor VIII inhibitor concentration if expected plasma Factor VIII activity levels are not attained, or if bleeding is not controlled as expected with administered dose ( 5.2 , 5.5 ). 5.1 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis, are possible with KOVALTRY. Early signs of hypersensitivity reactions, which can progress to anaphylaxis, may include chest or throat tightness, dizziness, mild hypotension and nausea. Discontinue KOVALTRY if symptoms occur and seek immediate emergency treatment. KOVALTRY may contain trace amounts of mouse and hamster proteins [see Description ( 11 )] . Patients treated with this product may develop hypersensitivity to these non-human mammalian proteins. 5.2 Neutralizing Antibodies Neutralizing antibody (inhibitor) formation has occurred following administration of KOVALTRY. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all Factor VIII products [see Adverse Reactions ( 6.1 )]. Carefully monitor patients for the development of Factor VIII inhibitors, using appropriate clinical observations and laboratory tests. If expected plasma Factor VIII activity levels are not attained or if bleeding is not controlled as expected with administered dose, suspect the presence of an inhibitor (neutralizing antibody) [see Warnings and Precautions ( 5.5 )]. 5.3 Cardiovascular Risk Factors Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with Factor VIII. 5.4 Catheter-related Infections Catheter-related infections may be observed when KOVALTRY is administered via central venous access devices (CVADs). These infections have not been associated with the product itself. 5.5 Monitoring Laboratory Tests • Monitor plasma Factor VIII activity levels using a validated test to confirm that adequate Factor VIII levels have been achieved and maintained [see Dosage and Administration ( 2.1 )] . • Monitor for development of Factor VIII inhibitors. Perform a Bethesda inhibitor assay if expected Factor VIII plasma levels are not attained or if bleeding is not controlled with the expected dose of KOVALTRY. Use Bethesda Units (BU) to report inhibitor titers.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most frequently reported adverse reactions in clinical trials (≥5%) were inhibitors in previously untreated patients (PUPs)/minimally treated patients (MTPs), pyrexia, headache, and rash (see Table 3 ). The most frequently reported adverse reactions in clinical trials (≥5%) were inhibitors in previously untreated patients (PUPs)/minimally treated patients (MTPs), pyrexia, headache, and rash ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare at 1-888-842-2937 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety profile of KOVALTRY was evaluated in 236 (193 previously treated (PTPs), 43 PUPs/MTPs) patients, inclusive of 94 pediatric patients <12 years of age. The safety analysis was done using a pooled database from three multi-center, prospective, open-label clinical studies. The median time on clinical trial for the pooled safety population was 558 days with a median of 183 exposure days (EDs). The majority of patients (N=201) accumulated ≥ 100 EDs. The total number of exposure days to KOVALTRY for all treatments including peri-operative management was 65029 EDs. Subjects who received KOVALTRY for perioperative management (N=5) with treatment period of 2 to 3 weeks and those who received single doses of KOVALTRY for PK studies (N=6) were excluded from the pooled safety analysis. Table 3 lists the adverse reactions reported during clinical studies. For PTPs, the frequency, type, and severity of adverse reactions in children are similar to those in adults. Table 3: Adverse Reactions from pooled clinical studies (all age groups): Clinical trials 1, 2, and 3) (N=236) MedDRA Primary System Organ Class Preferred term Frequency of Adverse Drug Reactions N (%) Blood and the Lymphatic System Disorders Lymphadenopathy 2 (0.8%) Cardiac Disorders Palpitation Sinus tachycardia 2 (0.8%) 2 (0.8%) Gastrointestinal Disorders Abdominal pain Abdominal discomfort Dyspepsia 9 (3.8%) 3 (1.3%) 4 (1.7%) General Disorders and Administration Site Conditions Pyrexia Chest discomfort Injection site reactions Includes injection site extravasation and hematoma, infusion site pain, pruritus, and swelling 22 (9.3%) 2 (0.8%) 6 (2.5%) Immune System Disorders Hypersensitivity 1 (0.4%) Nervous System Disorders Dizziness Dysgeusia Headache 3 (1.3%) 1 (0.4%) 20 (8.5%) Psychiatric Disorders Insomnia 5 (2.1%) Skin and Subcutaneous Tissue Disorders Dermatitis allergic Pruritus Rash Includes rash, rash erythematous, rash pruritic, and rash vesicular Urticaria 2 (0.8%) 6 (2.5%) 13 (5.5%) 3 (1.3%) Vascular disorders Flushing 1 (0.4%) In PTPs (N=193), Factor VIII inhibitors occurred in 1 patient at a frequency of 0.5% (1/193) and in PUPs/MTPs (N=43) with a frequency of 54.8% (23/42); inhibitor analysis was based on 42 of 43 PUPs/MTPs, as one patient was unevaluable for inhibitor analysis and thus excluded. Immunogenicity All clinical trial subjects were monitored for neutralizing antibodies (inhibitors) to Factor VIII by the modified Bethesda assay using blood samples obtained prior to the first infusion of KOVALTRY, at defined intervals during the studies and at the completion visit. Clinical trials with KOVALTRY evaluated a total of 204 treated pediatric and adult patients diagnosed with severe hemophilia A (Factor VIII <1%) with previous exposure to Factor VIII concentrates ≥50 EDs, no PTP developed neutralizing antibodies to Factor VIII. One case of transient low titer inhibitor (0.6 BU/mL (peak titer: 1.0 BU/mL)) occurred in a 13 year old PTP after 549 EDs concurrent with an acute infection and positive IgG anticardiolipin antibodies. The Factor VIII recovery was normal (2.7 IU/dL per IU/kg), annualized bleeding rate (ABR) was zero, and no change in therapy was required. In the main phase of the clinical trial in PUPs/MTPs, Factor VIII inhibitors were detected in 23 of 42 patients (54.8%, 95% CI: 39 to 70%) with a median (range) of 9 (4-42) EDs at the time of the first positive inhibitor test. Of these, 6 (14.3%) patients had low titer inhibitors (≤ 5.0 BU) who continued on treatment and had negative inhibitor results at the end of the study. In 17 (40.5%) patients who developed high titer inhibitors (> 5.0 BU), high-risk mutations for inhibitor development were identified in 12 (85.7%) of 14 patients with available FVIII mutation data. The detection of antibody formation is dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, it may be misleading to compare the incidence of antibodies to KOVALTRY with the incidence of antibodies to other products.

adverse reactions table

<table width="63.08%"><caption>Table 3: Adverse Reactions from pooled clinical studies (all age groups): Clinical trials 1, 2, and 3) (N=236)</caption><col width="55%"/><col width="16%"/><thead><tr><th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="top"><content styleCode="bold">MedDRA Primary System Organ Class</content> <content styleCode="bold">Preferred term</content></th><th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"><content styleCode="bold">Frequency of Adverse Drug Reactions</content> <content styleCode="bold">N (%)</content></th></tr></thead><tbody><tr><td styleCode="Rrule Lrule Toprule " valign="top"><paragraph><content styleCode="bold">Blood and the Lymphatic System Disorders</content></paragraph></td><td styleCode="Rrule Lrule Toprule " valign="top"/></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Lymphadenopathy</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>2 (0.8%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Cardiac Disorders</content></paragraph></td><td styleCode="Rrule Lrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Palpitation</paragraph><paragraph>Sinus tachycardia</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>2 (0.8%)</paragraph><paragraph>2 (0.8%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Gastrointestinal Disorders</content></paragraph></td><td styleCode="Rrule Lrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Abdominal pain</paragraph><paragraph>Abdominal discomfort</paragraph><paragraph>Dyspepsia</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>9 (3.8%)</paragraph><paragraph>3 (1.3%)</paragraph><paragraph>4 (1.7%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">General Disorders and Administration Site Conditions</content></paragraph></td><td styleCode="Rrule Lrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Pyrexia</paragraph><paragraph>Chest discomfort</paragraph><paragraph>Injection site reactions<footnote ID="_Ref88647043">Includes injection site extravasation and hematoma, infusion site pain, pruritus, and swelling</footnote></paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>22 (9.3%)</paragraph><paragraph>2 (0.8%)</paragraph><paragraph>6 (2.5%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Immune System Disorders</content></paragraph></td><td styleCode="Rrule Lrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Hypersensitivity</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>1 (0.4%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Nervous System Disorders</content></paragraph></td><td styleCode="Rrule Lrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Dizziness</paragraph><paragraph>Dysgeusia</paragraph><paragraph>Headache</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>3 (1.3%)</paragraph><paragraph>1 (0.4%)</paragraph><paragraph>20 (8.5%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Psychiatric Disorders</content></paragraph></td><td styleCode="Rrule Lrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Insomnia</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>5 (2.1%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content></paragraph></td><td styleCode="Rrule Lrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Dermatitis allergic</paragraph><paragraph>Pruritus</paragraph><paragraph>Rash<footnote ID="_Ref88647074">Includes rash, rash erythematous, rash pruritic, and rash vesicular</footnote></paragraph><paragraph>Urticaria</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>2 (0.8%)</paragraph><paragraph>6 (2.5%)</paragraph><paragraph>13 (5.5%)</paragraph><paragraph>3 (1.3%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Vascular disorders</content></paragraph></td><td styleCode="Rrule Lrule " valign="top"/></tr><tr><td styleCode="Rrule Botrule Lrule " valign="top"><paragraph>Flushing</paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="top"><paragraph>1 (0.4%)</paragraph></td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.